EANS-Adhoc: - Marseille-Kliniken Group disposing of its rehabilitation division - The transaction includes all rehabilitation clinics with a total of 1,269 beds - Sale generates a book gain in a lower double-digit EUR million range

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

21.04.2010

Berlin, 21 April 2010. Marseille-Kliniken Group (Prime Standard, ISIN DE
0007783003, MKA) has, as already announced some time ago, disposed of all
rehabilitation clinic operations, thereby discontinuing the Group´s
rehabilitation business. The closing of the sale depends on the approval of the
annual general meeting of Karlsruhe Sanatorium AG as well as the lessor´s
consent. This is to be completed by the beginning of May 2010. Capacities of
1,269 beds at seven locations in Germany are being sold.

The transaction is impacting the investments in the rehabilitation clinics
operated by Karlsruhe Sanatorium AG, a subsidiary of Marseille-Kliniken AG. It
includes the Gotthard-Schettler-Klinik and REHA-Klinik Sigmund Weil, both
located in Bad Schönborn, the specialist clinic for mental conditions Ortenau in
Zell am Harmersbach, the clinic in Bad Herrenalb, the specialist clinic for
psychosomatic conditions Schömberg as well as the psychosomatic clinic Kinzigtal
in Gengenbach. Marseille-Kliniken AG also disposed of its investments in the
rehabilitation companies Algos Fachklinik in Bad Klosterlausnitz, the sports and
rehabilitation center Harz and Teufelsbad specialist clinic Blankenburg, both in
Blankenburg/Harz. The clinic locations are each operated as limited companies
(GmbH) and their shares were sold as part of this transaction.

In return, Marseille-Kliniken Group will be recording a significant book gain
amounting to a lower double-digit EUR million scope. Both parties agreed not to
disclose the exact purchase amount involved.

Marseille-Kliniken Group is making the sale to a joint venture held by funds
which financial investor AUCTUS Capital Partners AG consults, and the existing
management team around CEO Berthold Müller and Medical Director Professor Dr.
Ulrich T. Egle and Professor Dr. Bernd E. Fromm. AUCTUS is Germany´s leading SME
investment company and commands considerable expertise in the field of
healthcare.

The Rehabilitation division is profitable, it has not been part of the core
business of Marseille-Kliniken Group in the recent past. The company has been
reviewing a sale of the division for some time as a result. Generated inflows
are to be invested in further developing the Care core business.

End of ad hoc release

Further inquiry note:
Hillermann Consulting
Christian Hillermann
Investor Relations for Marseille-Kliniken AG
Poststraße 14/16
20354 Hamburg
Germany
Tel.: +49-(0)40 / 320 279-10
Fax: +49-(0)40 / 320 279-114
www.hillermann-consulting.de

Marseille-Kliniken AG
Dr. Ute Buchheim
Friedrich-Ebert-Str. 65
33330 Gütersloh
Germany
Tel.: +49-(0)5241 / 90 39-35
Fax: +49-(0)5241 / 90 39-39
www.marseille-kliniken.com
end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer:   Marseille-Kliniken AG
          Alte Jakobstraße 79/80
          D-10709 Berlin
phone:    +49 (0)30 246 32-400 
FAX:      +49 (0)30 246 32-401
mail:     [email protected]
WWW:      http://www.marseille-kliniken.de
sector:   Pharmaceuticals
ISIN:     DE0007783003
indexes:  CDAX, Classic All Share, Prime All Share

stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Stuttgart, Düsseldorf, regulated dealing: Hamburg
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | OTB

print